BSC Buys Target; Sulzer Medica Spins Off
For the last couple of years, one of the most closely-watched battles in the medical device industry was that between Target Therapeutics Inc., with 1996 sales of $47.5mm, and its much larger competitors, Boston Scientific Corp. and Johnson & Johnson in the struggle for the market for miniature catheters used in minimally-invasive applications, particularly interventional neurology.
You may also be interested in...
Thermo Fisher Scientific has agreed to buy Mesa Biotech for $450m in cash and Hillrom will acquire Bardy Diagnostics for $375m in cash. Both deals will add complementary digital health solutions, which may be a continued trend in 2021.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Medicare now covers transcatheter edge-to-edge repair for both functional and degenerative mitral regurgitation under specific conditions.